Sanofi refiles $3.2B Translate Bio buyout with FTC to allow more time for review

Ever since the Federal Trade Commission (FTC) unveiled its campaign to take a closer look at biopharma's M&A strategies, the industry's dealmakers have been on high alert. While deals have so far gone through without hiccups, Sanofi and Translate Bio are refiling paperwork on their $3.2 billion merger to give the agency more time to review.